Form Filed By Hakim Nasrat A
Mon, Aug 24, 2020
Go to original document
ELITE PHARMACEUTICALS INC /NV/ (ELTP)
Healthcare
Drug Manufacturers—Specialty & Generic
Insights
Coming soon
Non Derivative Transactions
2020-08-24
Common Stock
Derivative Conversion
C
Type
Acquired 158,017,328 shares @ $0.00 per share
167,114,880 shares
Direct
Common Stock
Other
Type
Disposed 0 shares @ $0.00 per share
2,700,000 shares
by IRA
Indirect
Footnotes
1. The preferred shares are convertible into shares of common stock at a rate of 6,576,878.18 shares of common stock for each whole share of preferred stock, effectively $0.1521 per share of common stock.
2. Shareholder Approval was obtained on June 23, 2020 for an increase in the number of authorized shares of common stock to permit full conversion of the preferred stock.
3. None